EICHOR
● Available
Intermediate-size Patient Population Expanded Access Protocol
Condition: ALS (Amyotrophic Lateral Sclerosis) · Sponsor: Spinogenix
About this study
The purpose of this Expanded Access Program is to provide tazbentetol to ALS patients who are not eligible to enroll in an ALS clinical trial. This Expanded Access Program will assess safety and tolerability, and clinical efficacy of tazbentelol.
This description comes directly from the study's public registry record.
Talk to the study team
Project Lead · 1 (661) 862-7122 · als302eap@cbcc.global
Spinogenix Lead, PhD · 1 310 853-5695 · studyiseap@spinogenix.com
Always discuss trial participation with your own doctor first.
Locations (15)
| University of Alabama Birmingham | Birmingham, Alabama, United States | Available |
| Mayo Scottsdale | Scottsdale, Arizona, United States | Available |
| Kaiser Permanente Los Angeles | Los Angeles, California, United States | Available |
| Cedar-Sinai Medical Center | Los Angeles, California, United States | Available |
| California Pacific Medical Center | San Francisco, California, United States | Available |
| Nova Southeastern University | Davie, Florida, United States | Available |
| Synapticure | Chicago, Illinois, United States | Available |
| Dartmouth-Hitchcock Medical Center | Lebanon, New Hampshire, United States | Available |
| Atlantic Health | Summit, New Jersey, United States | Available |
| New Mexico VA Health Care System | Albuquerque, New Mexico, United States | Available |
| NYU Langone Health | New York, New York, United States | Available |
| Columbia University Medical Center | New York, New York, United States | Available |
+ 3 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07088159